|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
1-N'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
International Nonproprietary Names ![]() |
|
INN number | INN |
10216 | sitravatinib |
Synonyms ![]() |
GCD-516 | GCD516 | MGCD516 |
Comments |
Sitravatinib (MGCD516) is an inhibitor of multiple receptor tyrosine kinases (RTKs) that was developed as an antineoplatic agent [1]. It targets several RTKs (e.g. c-Met, PDGFR, c-Kit and IGF1-R) whose overexpression has been shown to drive sarcoma cell growth |
Database Links ![]() |
|
CAS Registry No. | 1123837-84-2 (source: WHO INN record) |
GtoPdb PubChem SID | 363894214 |
PubChem CID | 25212148 |
Search Google for chemical match using the InChIKey | WLAVZAAODLTUSW-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | WLAVZAAODLTUSW |
Search PubMed clinical trials | sitravatinib |
Search PubMed titles | sitravatinib |
Search PubMed titles/abstracts | sitravatinib |
Search UniChem for chemical match using the InChIKey | WLAVZAAODLTUSW-UHFFFAOYSA-N |
Search UniChem for chemicals with the same backbone | WLAVZAAODLTUSW |